PropertyValue
?:definition
  • A humanized monoclonal antibody directed against human vascular endothelial growth factor (VEGF), with potential anti-angiogenic and antineoplastic activities. Upon administration, anti-VEGF monoclonal antibody hPV19 targets and binds to VEGFR at a unique binding site and inhibits VEGF binding to its receptors, VEGFR1 and VEGFR2, thereby preventing VEGF/VEGFR-mediated signaling. This prevents the growth and maintenance of tumor blood vessels. This decreases nutrient supply to tumor cells, resulting in tumor cell death. Increased VEGF/VEGFR signaling is associated with increased invasiveness and decreased survival.
?:hasCUIAnnotation
?:hasGeneratedBy
?:type

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/C4733677_NCI>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/C4733677_NCI>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all